Haemonetics LN9000-110-EWC, Operation Manual

Page: 3 / 110

iii
P/N 85213-30, Manual revision: B
C
ONSUMER INFORMATION
Proprietary rights
The contents of this manual are property of the Haemonetics Corporation.
Haemonetics
® , MCS ® + and eLynx
™
are trademarks or registered trademarks of
the Haemonetics Corporation in the United States, other countries, or both. Any
information or descriptions contained in this manual may not be reproduced and
released to any of the general public, or used in conjunction with any profes-
sional instruction without written consent of Haemonetics Corporation, USA.
Please direct any written inquiries to the appropriate address.
International Headquarters Corporate Headquarters
Haemonetics SA Haemonetics Corporation
Signy Centre, rue des Fléchères 400 Wood Road
P.O. Box 262, 1274 Signy 2, Switzerland Braintree, MA 02184, USA
Tel. [+41 22] 363 90 11
Tel. [+1 781] 848 7100
Fax [+41 22] 363 90 54 Fax [+1 781] 848 5106
Legal disclaimer
This manual is intended for use as a guide, uniquely for material as supplied by
the Haemonetics Corporation. It provides the operator with necessary informa-
tion to safely carry out specific procedures and satisfactorily maintain Haemo-
netics produced equipment. The manual is to be used in conjunction with
instruction and training as supplied by qualified Haemonetics personnel.
Haemonetics guarantees its products when correctly used by a properly trained
operator. Any failure to respect the procedures as described could result in
impaired function of the equipment, as well as in injury to the operator and/or
patient/donor. Haemonetics accepts no responsibility for problems resulting from
failure to comply with prescriptions as outlined by the company.
Any modifications estimated as necessary by the customer should be evaluated
by a Haemonetics Clinical Specialist.
Safe utilization of Haemonetics material and equipment requires the operator to
correctly handle and dispose of blood-contaminated material. The operator of
any Haemonetics equipment must fully understand and implement the local
prevailing policies and procedures of each facility in which Haemonetics prod-
ucts are used, concerning blood-contaminated material as well as blood prod-
ucts.
It remains solely the responsibility of the customer to fully assess and ensure the
safety of any products obtained from Haemonetics prescribed procedures, prior
to further application or use.
Haemonetics declines any responsibility for choices made by the consumer
concerning the utilization of these products and by-products.
In addition, it is the responsibility of the apheresis center using Haemonetics
equipment and material to provide information to the donor concerning the risks
involved with any apheresis procedure. Prior to initiating any procedure, the
apheresis center is responsible to verify that the donor understands these risks
and consents to the procedure.